Publications by the researcher in collaboration with JOSÉ ÁNGEL GARCÍA SÁENZ (29)

2026

  1. Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

    Journal of the National Cancer Institute, Vol. 118, Núm. 2, pp. 354-359

2025

  1. Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

    Oncologist, Vol. 30, Núm. 9

  2. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

    Annals of Oncology, Vol. 36, Núm. 2, pp. 158-171

2024

  1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

  2. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort

    Breast Cancer Research and Treatment, Vol. 206, Núm. 3, pp. 551-559

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

2022

  1. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

    Cancers, Vol. 14, Núm. 3

2021

  1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724

2019

  1. Breast cancer PAM50 signature: Correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

    BMC Genomics, Vol. 20, Núm. 1

  2. Concordance of genomic variants in matched primary breast cancer, metastatic tumor, and circulating tumor DNA: The Mirror study

    JCO Precision Oncology, Vol. 3

  3. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

    Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829

  3. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification

    Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852

  4. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

2017

  1. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

  2. Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial (Breast Cancer Research and Treatment, (2016), 156, 3, (507-515), 10.1007/s10549-016-3792-1)

    Breast Cancer Research and Treatment

  3. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer

    Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189

2016

  1. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

    Breast Cancer Research and Treatment, Vol. 156, Núm. 3, pp. 507-515